BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:bleximenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of bleximenib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04811560-3019@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:bleximenib: Phase 1/2 readout est. (NCT04811560)
DESCRIPTION:bleximenib\, phase 1/2.\nStudy: A Phase 1/2 Study of Bleximenib
  in Participants With Acute Leukemia (cAMeLot-1)\nEstimated primary comple
 tion: 29 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bleximenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04811560
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06852222-3019@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:bleximenib: Phase 3 readout est. (NCT06852222)
DESCRIPTION:bleximenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Bleximenib\, Venetoclax and Azacitidine For Treatment of Participants W
 ith Newly Diagnosed Acute Myeloid Leukemia (AML)\nEstimated primary comple
 tion: 22 June 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 leximenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06852222
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223814-3019@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:bleximenib: Phase 3 readout est. (NCT07223814)
DESCRIPTION:bleximenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Bleximen
 ib in Combination With Standard Induction and Consolidation Therapy Follow
 ed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (A
 ML)\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bleximenib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07223814
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-3019@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:bleximenib: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:bleximenib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study 
 of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary 
 completion: December 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bleximenib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03013998
URL:https://assetmemo.bio/drug/bleximenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
